- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-NVR: MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 63.00 |
---|---|
High | 63.00 |
Low | 63.00 |
Bid | 65.20 |
Offer | 66.80 |
Previous close | 63.80 |
Average volume | 86.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 30 2024 07:06 BST.
More ▼